Spots Global Cancer Trial Database for epcoritamab
Every month we try and update this database with for epcoritamab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Expanded Access Program for Epcoritamab | NCT05733650 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High Grade B-ce... Grade 3B Follic... | Epcoritamab | 18 Years - | Genmab | |
| Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | NCT05848765 | Relapsed Follic... Refractory Foll... | Epcoritamab Lenalidomide Rituximab Obinutuzumab Bendamustine Vincristine Doxorubicin Cyclophosphamid... Prednisone Investigation a... Investigation a... | 18 Years - | University of Birmingham | |
| Expanded Access Program for Epcoritamab | NCT05733650 | Large B-cell Ly... Diffuse Large B... Primary Mediast... High Grade B-ce... Grade 3B Follic... | Epcoritamab | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) | NCT05578976 | Diffuse Large B... | Epcoritamab Cyclophosphamid... Rituximab Vincristine Doxorubicin Prednisone | 18 Years - 79 Years | Genmab | |
| A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL | NCT04628494 | Diffuse Large B... | Epcoritamab Investigator's ... | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | NCT05283720 | Non-Hodgkin Lym... | Epcoritamab Lenalidomide Ibrutinib Rituximab Cyclophosphamid... Doxorubicin Hyd... Prednisone Polatuzumab Ved... Venetoclax CC-99282 | 18 Years - | Genmab | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab | |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | NCT04358458 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Small Lymphocyt... Mantle Cell Lym... Chronic Lymphoc... High-grade B-ce... Primary Mediast... | GEN3009 Epcoritamab | 18 Years - | Genmab | |
| Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy | NCT06238648 | Diffuse Large B... Primary Mediast... Transformed Ind... | Biopsy Biospecimen Col... Computed Tomogr... Epcoritamab Magnetic Resona... Patient Observa... Positron Emissi... | 18 Years - | Academic and Community Cancer Research United | |
| First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | NCT04358458 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Small Lymphocyt... Mantle Cell Lym... Chronic Lymphoc... High-grade B-ce... Primary Mediast... | GEN3009 Epcoritamab | 18 Years - | Genmab | |
| Epcoritamab and Rituximab for First-line Follicular Lymphoma | NCT05783609 | Follicular Lymp... Low Grade Non-H... | Epcoritamab Rituximab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | NCT05201248 | B-Cell Non-Hodg... | Epcoritamab Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Lenalidomide | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | NCT05451810 | Diffuse Large B... Classic Follicu... | Epcoritamab | 18 Years - | Genmab | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | NCT06191744 | Follicular Lymp... | Epcoritamab Prednisone Rituximab Lenalidomide Doxorubicin Vincristine Cyclophosphamid... Obinutuzumab Bendamustine | 18 Years - | AbbVie | |
| First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma | NCT03625037 | DLBCL High-grade B-ce... Primary Mediast... FL MCL Small Lymphocyt... Marginal Zone L... | Epcoritamab | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma | NCT05201248 | B-Cell Non-Hodg... | Epcoritamab Cyclophosphamid... Rituximab Doxorubicin Vincristine Prednisone Lenalidomide | 18 Years - | Genmab | |
| A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma | NCT05451810 | Diffuse Large B... Classic Follicu... | Epcoritamab | 18 Years - | Genmab | |
| Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma | NCT05852717 | Large Cell Lymp... Relapsed Cancer Refractory Canc... | AutoSCT OR CAR ... GDP Epcoritamab | 18 Years - | Hoosier Cancer Research Network | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | NCT06191744 | Follicular Lymp... | Epcoritamab Prednisone Rituximab Lenalidomide Doxorubicin Vincristine Cyclophosphamid... Obinutuzumab Bendamustine | 18 Years - | AbbVie | |
| Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | NCT06112847 | Follicular Lymp... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Electronic Heal... Epcoritamab Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - | City of Hope Medical Center | |
| Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma | NCT06045247 | Large B-cell Ly... | Prednisone Rituximab Cyclophosphamid... Vincristine Epcoritamab | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma | NCT05409066 | Follicular Lymp... | Epcoritamab Rituximab Lenalidomide | 18 Years - | Genmab | |
| Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL | NCT06287398 | DLBCL - Diffuse... High-grade B-ce... High Grade B-Ce... DLBCL, Nos Gene... High Grade B-Ce... Follicular Larg... Follicular Larg... | Epcoritamab | 18 Years - | Australasian Leukaemia and Lymphoma Group |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
